Radek Ampapa

Jihlava, VY, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Causal effects of multiple sclerosis therapies in left-truncated registry data.

Causal effects of multiple sclerosis therapies in left-truncated registry data.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 21, 2026

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: April 28, 2026

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: January 13, 2026

Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.

Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.

Journal: Therapeutic advances in neurological disorders

Published: November 09, 2025

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.

Journal: Journal of neurology

Published: November 01, 2025

Predicting disease progression in multiple sclerosis with clinically accessible information and technology.

Predicting disease progression in multiple sclerosis with clinically accessible information and technology.

Journal: Journal of neurology

Published: September 16, 2025

Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).

Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 07, 2025

Steroidomic Changes in the Cerebrospinal Fluid of Women with Multiple Sclerosis.

Steroidomic Changes in the Cerebrospinal Fluid of Women with Multiple Sclerosis.

Journal: International journal of molecular sciences

Published: May 01, 2025

Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.

Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: April 15, 2025

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.

Journal: JAMA neurology

Published: April 14, 2025

Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years.

Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: March 25, 2025

Epidemiology, diagnosis and outcomes of acquired demyelinating syndromes in children: A Czech perspective.

Epidemiology, diagnosis and outcomes of acquired demyelinating syndromes in children: A Czech perspective.

Journal: Multiple sclerosis and related disorders

Published: February 17, 2025

Showing 1-12 of 53

Last Updated: 09/26/2026